SCWorx Corp.

The stock is in a deep long-term downtrend, still far below its 200-day average and well off its 52-week high. The recent bounce has only brought it back into the lower part of a volatile range, so the setup remains a turnaround attempt rather than a confirmed trend reversal.

No analyst consensus or price target is available, and there have been no recent rating changes. That leaves the tape without a Street anchor, so shareholders should focus on whether the business can stabilize fundamentals before expecting a rerating.

Earnings have been consistently negative, with the last four reported quarters showing EPS of -1.3549, -1.9653, -8.5205, and -0.15. With no estimates on file, the key watchpoint is whether revenue can keep growing and whether losses narrow from the current pattern.

No recent insider transactions were reported. With no discretionary buying or selling to interpret, there is no insider signal to lean on for direction.

Profitability remains weak, with a -17.13% operating margin and -80.54% net margin, even though gross margin is 44.7%. Revenue grew 3.4% year over year, but operating cash flow was -$1.54 million and free cash flow was -$1.53 million, keeping the balance sheet and cash burn in focus.

SCWorx sits in healthcare information services, where scale and recurring software economics usually matter most. Its current valuation is hard to benchmark cleanly, but the market is pricing it more like a distressed microcap than a typical health IT peer.